Ion Beam Applications SA (LON:0GZK)
United Kingdom · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 391.86M +43.6% |
| Revenue (ttm) | 550.23M +7.1% |
| Net Income | 21.19M +44.7% |
| EPS | 0.67 +38.9% |
| Shares Out | n/a |
| PE Ratio | 20.35 |
| Forward PE | 19.82 |
| Dividend | 0.15 (1.12%) |
| Ex-Dividend Date | Jun 15, 2026 |
| Volume | 1,808 |
| Open | 16.60 |
| Previous Close | 16.14 |
| Day's Range | 15.92 - 16.60 |
| 52-Week Range | 9.91 - 17.72 |
| Beta | 1.23 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 26, 2026 |
About Ion Beam Applications
Ion Beam Applications SA designs, produces, and markets solutions for cancer diagnosis and treatments, serious illnesses, and industrial applications in Belgium, the United States, China, Germany, and India. It operates through four segments, Clinical Proton Therapy; Clinical Dosimetry; IBA Technologies; and IBA Corporate. The company develops ConformalFLASH, a novel technique using the proton Bragg peak; DynamicARC, a technique that allows dynamic spot scanning irradiation and energy switching while the gantry is rotating; Proteus ONE, a compa... [Read more]
Financial Performance
In 2025, Ion Beam Applications's revenue was 620.18 million, an increase of 24.49% compared to the previous year's 498.16 million. Earnings were 12.73 million, an increase of 37.59%.
Financial numbers in EUR Financial StatementsNews
Ion Beam Applications Earnings Call Transcript: Q2 2026
Revenue and profitability improved significantly in H1 2026, with adjusted EBIT up to EUR 17.6 million and net result positive at EUR 9.3 million. Strong order intake in proton therapy and radiopharma offset challenges in Dosimetry and Industrial Solutions, while guidance for at least EUR 32 million adjusted EBIT in 2026 is reiterated.
Ion Beam Applications Earnings release: Q2 2026
Ion Beam Applications released its Q2 2026 earnings on August 27, 2026, summarizing the period's financial results.
Ion Beam Applications Slides: Q2 2026
Ion Beam Applications has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 27, 2026.
Ion Beam Applications Earnings release: Q1 2026
Ion Beam Applications released its Q1 2026 earnings on May 21, 2026, summarizing the period's financial results.
Ion Beam Applications Earnings Call Transcript: H2 2025
Record 2025 revenue and EBIT were driven by strong backlog conversion, proton therapy profitability, and strategic investments. Guidance for 2026 targets further EBIT growth and margin improvement, with legacy contract impacts expected to diminish and cash position to improve by 2027.
Ion Beam Applications Earnings release: H2 2025
Ion Beam Applications released its H2 2025 earnings on March 27, 2026, summarizing the period's financial results.
Ion Beam Applications Slides: H2 2025
Ion Beam Applications has posted slides in relation to its H2 2025 quarterly earnings report, which was published on March 27, 2026.
Ion Beam Applications Annual report: H2 2025
Ion Beam Applications has published its H2 2025 annual report on March 27, 2026.
Ion Beam Applications Earnings Call Transcript: Q3 2025
Order intake and backlog remain strong, supporting confidence in meeting EBIT guidance of at least $25 million. New financing enhances balance sheet flexibility, while segment performance is robust despite some headwinds in Dosimetry.
Ion Beam Applications Earnings release: Q3 2025
Ion Beam Applications released its Q3 2025 earnings on November 20, 2025, summarizing the period's financial results.
Ion Beam Applications Slides: Q3 2025
Ion Beam Applications has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 20, 2025.
IBA Business Update – Third Quarter 2023
Louvain-La-Neuve, Belgium, 16 November 2023 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology, today announces its business update for the third quarter...
IBA Reports Half Year 2022 Results
RECORD ORDER INTAKE AND BACKLOG ACROSS THE GROUP